In response to the ongoing COVID-19 pandemic, Erba today launched the ErbaMDx 
SARS-CoV-2 RT-PCR Kit for detection of SARS-CoV-2. 

To overcome challenges in older COVID-19 molecular tests, Erba's 
Cambridge(UK)-based development team has carefully engineered a new assay to 
improve detection and ease of use with a single tube multiplex mastermix, 
compatible with room-temperature storage and transportation.

The new assay offers 200 copies/ml LoD, using universally trusted gene targets 
highly specific for SARS-CoV-2 and updated primer sequences to maximise long 
term performance. Sample types include both nasopharyngeal and oropharyngeal 
swabs as well as saliva.

Nikhil Vazirani, MD of Erba, said: "We are proud and excited to add a highly 
sensitive RT-PCR test to our growing range of immunoassay and molecular 
solutions. The new ErbaMDx SARS-CoV-2 test perfectly complements our successful 
COVID-19 IgG and IgM ELISA assays to offer customers a state-of-the-art 
molecular test in addition to antibody testing which will offer clinicians 
valuable insight into the immune response to infection or vaccination."
The CE-marked kit will be available through Erba's global distribution network.

Learn more: https://covid19.erbamannheim.com/

About Erba Mannheim

Erba Mannheim is a global company focused on delivering innovative, affordable 
and sustainable diagnostic solutions to labs everywhere. Established in over 
100 countries, Erba group uses a combination of cutting-edge R&D in 4 
continents with efficient low-cost manufacturing to make diagnostic 
technologies accessible in all resource settings.

SOURCE: Erba Mannheim